From Japan comes a hospitality model in which architecture, technology and flexibility intertwine to redefine post-pandemic ...

Investing.com - Morgan Stanley upgraded Vertex Pharmaceuticals (NASDAQ:VRTX) from Equalweight to Overweight on Wednesday, raising its price target to $516.00 from $438.00. The new target represents ...

Robots may not be taking the place of researchers in lab coats running clinical trials anytime soon, but AI is playing an increasingly important role in drug discovery efforts. That’s the message ...

This strengthens Google’s position against rivals such as Microsoft and AWS as enterprises seek faster, more reliable ways to deploy and manage AI agents. Google Cloud has updated its Vertex AI Agent ...

During Vertex’s third-quarter presentation, Chief Commercial Officer Duncan McKechnie cited several numbers that suggest the launch of its long-awaited, non-opioid pain reliever Journavx is trending ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A former executive at Microsoft ...

President Trump released a video statement after Hamas said it was ready to release the remaining hostages in Gaza, if certain conditions were met first. Photo: Andrew Leyden/ZUMA Press Two years ...

Even amid political pressure from RFK Jr. and President Trump, as well as failed clinical data on VX-993, Vertex continues to strengthen its position in the cystic fibrosis market. Sales of its three ...

Aug. 25 (UPI) --The Japanese film Isolated, which screened Sunday at Big Bad Film Fest, is a relentless yakuza action film that remains focused as it builds exponential challenges for its hero. The ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit a snag on its path to expand the potential blockbuster’s reach into ...

Vertex Pharmaceuticals (NASDAQ:VRTX) shares fell in premarket trading on Tuesday after the company's VX-993 failed to meet the primary endpoint in the Phase 2 pain study, offsetting a strong quarterly ...